Business Context and Reporting Period
This Form 8-K is a current report filed by MEDICINOVA INC on November 8, 2006. The filing addresses a corporate governance event regarding the appointment of a principal officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Shintaro Asako as Chief Financial Officer (CFO) by the Board of Directors on November 8, 2006. Prior to this appointment, Mr. Asako served as the company's Vice President, Accounting and Administration (November 2005 to November 2006) and Vice President, Accounting and Financial Reporting (July 2005 to October 2005).
Management Commentary and Background
Management highlights Mr. Asako's extensive background in accounting and auditing:
- Education: Graduate of the Leventhal School of Accounting at the University of Southern California.
- Certifications: Certified Public Accountant (California) and member of the American Institute of Certified Public Accountants.
- Previous Experience:
- Audit Senior Manager at KPMG LLP (October 2004 to July 2005), focusing on multinational clients in pharmaceuticals and manufacturing.
- Supervisory Senior Auditor and Audit Manager at KPMG LLP (June 2002 to September 2004).
- Four years of audit and tax advisory experience at Arthur Andersen LLP.
The filing incorporates a press release issued on November 9, 2006, as Exhibit 99.1.
Investor Verification Checklist
- Verify the effective date of Shintaro Asako's tenure as CFO (November 8, 2006).
- Review the attached press release (Exhibit 99.1) for additional strategic context regarding the leadership change.
- Confirm Mr. Asako's professional credentials and prior employment history as stated in the filing.